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Developing novel drugs against the unicellular parasite Plasmodium is complicated by the paucity of
simple screening systems. Heat-shock proteins are an essential class of proteins for the parasite’s cyclical
life style between different cellular milieus and temperatures. The molecular chaperone Hsp90 assists a
large variety of proteins, but its supporting functions formany proteins that are important for cancer have
made it into a well-studied drug target. With a better understanding of the differences between Hsp90 of
the malarial parasite and Hsp90 of its human host, new therapeutic options might become available. We
have generated a set of isogenic strains of the budding yeast Saccharomyces cerevisiae where the essential
yeast Hsp90 proteins have been replaced with either of the two human cytosolic isoforms Hsp90 or
Hsp90, or with Hsp90 from Plasmodium falciparum (Pf). All strains express large amounts of the Flag-
taggedHsp90proteins and are viable. Even though the strainwith PfHsp90 growsmore poorly, it provides
a tool to reconstitute additional aspects of the parasiteHsp90 complex and its interactionswith substrates
in yeast as a living test tube. Upon exposure of the set of Hsp90 test strains to the two Hsp90 inhibitors
radicicol (Rd) and geldanamycin (GA), we found that the strain with Pf Hsp90 is relatively more sensitive
to GA than to Rd compared to the strains with human Hsp90’s. This indicates that this set of yeast strains
could be used to screen for new Pf Hsp90 inhibitors with a wider therapeutic window.
1. Introduction
WHOestimates that over 3 billion people live under the threat of
malaria. The malarial parasite Plasmodium infects over 500 million
people annually, which results in 3 million deaths. Discovering and
developing new inhibitors, for example for Plasmodium falciparum
(Pf), is difﬁcult as screening depends on the costly and laborious
maintenance of parasite cultures and on determining parasitemia
in rodent models. New molecular targets and experimental sys-
tems would be a welcome addition to the toolbox. Since unicellular
parasites are exposed to extreme changes in their environment as
they cycle between host and vector, their heat-shock proteins may
play an important role. The molecular chaperone Hsp90 has been
shown to be essential for viability in organisms ranging from yeast
to mouse [1–3]. The life cycle of Pf has been shown to be blocked in
vitro with two chemically distinct Hsp90 inhibitors, radicicol (Rd)
and geldanamycin (GA), primarily at the transition from the Ring to
the trophozoite stage in erythrocytes [4–7]. The stage-speciﬁcity of
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the inhibition has been taken as an indication that the drugs might
inhibit primarily through the parasite Hsp90.
Because Hsp90 has been recognized as an Achilles heel of can-
cer cells, there are already a considerable number of drugs available
andmore are beingdeveloped, and clinical trials are currently being
conducted with GA derivatives [2,8,9]. These studies have provided
a lot of information on the pharmacology of such inhibitors, and
so far, they have revealed surprisingly few side effects. In addi-
tion, a recent study showed that Hsp90 inhibitors block infection
of tissue culture cells by a wide panel of different viruses [10]. Not
surprisingly, it has been suggested that the already available Hsp90
inhibitors could be further developed as anti-viral and anti-parasite
agents. Hsp90 is highly conserved as illustrated by the fact that GA
binds and inhibits both Pf and human Hsp90, and yet, within the
constraints of 63% sequence identity at the amino acid level, there
should be sufﬁcient sequence and structural differences to identify
inhibitors that are selective for the parasite Hsp90 [11].
The budding yeast Saccharomyces cerevisiae (S. cerevisiae) was
the ﬁrst organism forwhich itwas shown thatHsp90 is essential for
viability [12]. This genetically easily manipulable organism has two
genes, HSC82 and HSP82, which encode two 95% identical Hsp90
proteins. Interestingly, heterologous Hsp90 proteins from many
species are able to replace Hsp82 and Hsc82 of the budding yeast.
These include the two human cytosolic isoforms Hsp90 [13] and
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Hsp90 [14], Hsp90 from Trypanosoma cruzi [15], Drosophila [16],
Caenorhabditis elegans and Candida albicans [17]. S. cerevisiae lends
itself perfectly to explore the functional conservation of proteins
from other species, to study their homologous and heterologous
biochemical interactions, and to screen for novel species-speciﬁc
drugs. This provides the rationale for why we decided to generate
and to study an isogenic set of yeast strains with human and Pf
Hsp90.
2. Materials and methods
2.1. Plasmids
The backbone for all constructs is plasmid pRS313/GPD-PGK
(a gift from A. Kralli). It is derived from the low copy num-
ber CEN/ARS yeast expression vector pRS313 [18] by insertion of
the strong constitutive GPD promoter from the TDH3 gene and
the PGK1 terminator. Plasmid pHCA/hHsp90 for expression of
untagged human Hsp90 was derived from p2TG/hHsp90 [19]
and has been described before [20]. Plasmid pRS313/PfHsp90
for expression of untagged Pf Hsp90 was made by trans-
ferring the Hsp90 open reading frame (ORF) from plasmid
pGEX-PfHsp90 as a PCR fragment containing the sequence GGATC-
CAAAAA and an EcoRI site preceding and following the ORF,
respectively. For expression of Flag-tagged Hsp90 proteins, the
expression vector pHGF was derived from plasmid pRS313/GPD-
PGK by replacing the multiple cloning sequences encompassing
the BamHI and HindIII sites with the sequence GGATCGCCACC-
ATGGATTACAAAGATGATGATGATAAAGGGATCCAAGCTT (sequences
encoding initiator methionine and Flag tag are underlined). Hsp90
ORFs were inserted into the BamHI or HindIII sites of pHGF to gen-
erate plasmids pHGF/Hsp82, pHGF/PfHsp90, pHGF/HsHsp90 and
pHGF/HsHsp90 to express Flag-tagged yeast Hsp82 (one of the
two yeast Hsp90 isoforms), Pf Hsp90, human Hsp90 and Hsp90,
respectively.
2.2. Yeast strains
All strains are derived from strain pp30#10 [21], which has
the following genotype: MATa ade2-101-o his3-200 leu2-3,112
lys2-801-a trp1-289 ura3-52 hsc82::KanMx4 hsp82::KanMx4 /
2-HSC82-URA3. It carries deletions of the two yeast HSP90 genes
HSP82 and HSC82 and is kept alive by expression of Hsc82
from an episome. To sensitize the strain for Hsp90 inhibitors
[22], we deleted the gene encoding the export pump Pdr5 by
using homologous recombination to replace the coding region
with the loxP-LEU2-loxP cassette from plasmid pUG73 [23].
This generated yeast strain DP533. All others were derived
from DP533 by plasmid shufﬂing. Speciﬁcally, strains DP549,
DP551, DP552, DP553, DP554, and DP555, referred herein also
as P, , FY, FP, F, and F, contain plasmids pRS313/PfHsp90,
pHCA/hHsp90, pHGF/Hsp82, pHGF/PfHsp90, pHGF/HsHsp90,
andpHGF/HsHsp90, respectively. The strainswithhumanHsp90’s
being genetically highly similar, their correctness could also be
double-checked with isoform-speciﬁc antibodies (data not shown,
see also ref. [20]).
2.3. Preparation of yeast extracts and immunoblotting
Cells were grown to an OD600 of 0.7–0.8 in rich medium with
2% glucose and 200g/ml adenine (YAPD), collected and washed
with ice-cold water. Cell pellets were resuspended in 10mM
Tris–HCl pH 7.5, 50mM NaCl, 10mM MgCl2, 1mM EDTA, 1mM
DTT, 20% (v/v) glycerol, and a cocktail of protease inhibitors. Cells
were broken mechanically with glass beads, and cleared lysates
Fig. 1. Schematic representation of the isogenic set of Hsp90 tester strains. The
species are abbreviated as follows: Sc, Saccharomyces cerevisiae; Pf, Plasmodium fal-
ciparum; Hs, Homo sapiens. The dotted line below the list of Hsp90 proteins indicates
that this system can easily accommodateHsp90 proteins fromother species. Further
details are given in the text.




YAPD medium was used both for plates and for liquid cultures
and cells were grown at 30 ◦C. Cells were freshly grown from an
overnight inoculum to OD600 ∼0.5 before starting the assays. For
plate assays, 5l aliquots of a serial dilution series were spotted,
startingwith a dilution toOD600=0.05. Plateswere scanned after 3
and4days. For assayswith liquid cultures, triplicate samples of cells
were diluted to OD600=0.05 except for FY, which was diluted fur-
ther to 0.01. Cell densities were measured at appropriate dilutions
with a spectrophotometer at OD600. Where indicated, Rd and GA
were added from 10mM stocks in dimethyl sulfoxide (DMSO). The
untreated control plates and cultures received the same amount
of DMSO (vehicle) needed as a solvent for the samples with the
highest drug concentration.
3. Results
We used plasmid shufﬂing to replace the endogenous HSP90
genes of S. cerevisiae, HSC82 and HSP82, with HSP90 from differ-
ent species. The latter were expressed from a low copy plasmid
under the control of the strong constitutive GPD promoter. To facil-
itate the comparison of Hsp90 protein levels, we also generated
a set of strains expressing all Hsp90 proteins with an N-terminal
Flag tag (Fig. 1). All complemented strains proved to be sufﬁciently
viable (see below, and data not shown) to allow their in-depth anal-
ysis. Our strain sets included strains with Pf Hsp90, yeast Hsp82,
human Hsp90, and human Hsp90. It is noteworthy that a con-
tinued auxotrophic selection for maintenance of the episomes was
not necessary since the expression of an Hsp90 is essential for via-
bility. Hence, the HSP90 genes served themselves as a marker and
all strains could be grown in rich medium.
We proceeded to determine the relative levels of the different
Hsp90 proteins with an immunoblot experiment. Total cell extracts
were prepared from all strains and probed with a monoclonal anti-
body against the Flag tag (Fig. 2A). An extract from a strain with
untagged human Hsp90 (lane ) served as a negative control. By
comparison with the total cellular proteins revealed on the ﬁlter
by Ponceau S-staining, it is apparent that the levels of the four
Flag-tagged Hsp90 proteins are overall quite comparable, human
Hsp90being the lowestwith a2-folddifference compared to yeast
Hsp82. When a similar immunoblot was probed with antibodies
that are speciﬁc for yeast Hsp90, no signal could be detected in any
of the strains complemented with human or Pf Hsp90. The strain
expressing Flag-tagged yeast Hsp82 served as a positive control.
This result ascertained that the strains F, F and FP expressing
Flag-tagged human Hsp90, Hsp90 and Pf Hsp90, respectively,











Fig. 2. Immunoblot analysis of Hsp90 proteins. Equal amounts of extracts from
indicated strains were probed with a monoclonal against the Flag tag (panel A)
or antibodies against yeast Hsp90 (panel B). The leftmost lanes on the Ponceau S-
stained ﬁlters shown below the immunoblots in both panels are molecular weight
markers (sizes indicated in kDa). The relative band intensities of the Flag-tagged
Hsp90 proteins are 100%, 49%, 99% and 125% for FY, F, F and FP, respectively.
We had previously compared the growth of cells with tagged
or untagged yeast Hsp82 (data not shown) and had not noticed
any particular difference. Since pilot experiments indicated that
FP grew less well than FY (see below), we wanted to determine
whether the Flag tag might adversely affect complementation by
Pf Hsp90. Serial dilutions of equal numbers of cells of the two cor-
responding strains, P and Pf (with untagged and tagged Pf Hsp90,
respectively), were spotted onto solid medium (Fig. 3A). It became
clear that the Flag tag, if anything, slightly improved the function
(or expression) of Pf Hsp90.
Thus, having established that Hsp90 protein levels were not
too dissimilar and Flag-tagged versions of Hsp90 appropriate, we
could start testing our set of strains consisting of the four Flag-
tagged Hsp90 proteins. On plates, FP and F turned out to grow
considerably more slowly than FY and F although they eventu-
ally reached similar colony numbers and sizes. We realized that, if
we were going to use plate growth assays to assess the effects of
Hsp90 inhibitors, we would need more comparable cell densities.
We therefore chose to spot FP and F 1 day earlier than FY and
F. With this 1 day advance, all four strains grow to comparable
densities within an additional 4 days, FY being yet slightly more
vigorous (Fig. 3B). To obtain more quantitative data, growth assays
were repeated in liquid culture (Fig. 3C). In this case, all strainswere
subjected to identical conditions. These experiments conﬁrmed the
slow and vigorous growth of FP and FY, respectively. Ultimately, all
four strains reach similar saturatingdensities. Surprisingly, in liquid
culture the yeast strain with human Hsp90 (F) does not display
the prominent growth defect that is obvious on plates and grows
even slightly faster than F.
Next, we explored whether plate or liquid growth assays would
allowus to testHsp90 inhibitors and to identifydifferencesbetween
these tester strains. After pilot experimentswith a rangeof inhibitor
concentrations, we settled on concentrations that gave the largest
differences without completely obliterating growth of all strains
except the comparatively more resistant FY (data not shown). The
result of a growth assay on plates is shown in Fig. 4. It must be
pointed out again that F and FP were spotted 1 day earlier. How-
ever, thiswas thecase for all treatmentsand, therefore, their relative
sensitivities to the drugs can be compared. While FY is only slightly
affected by either 40M GA or 2M Rd, FP is exquisitely sensitive
to GA and to a lesser extent to 2M Rd. The strains with human
Hsp90 isoforms (F and F) are similarly affected and more resis-
tant to GA than FP. FP in turn is more resistant to Rd than both F
and F. As could be expected from the results discussed above, the
four strains behaved slightly differently in liquid medium (Fig. 5).
Although thedifferences inRd sensitivities betweenhuman (F and
Fig. 3. Growth assays with Hsp90 tester strains in the absence of Hsp90 inhibitors.
(A) Comparison of strainswith untagged and Flag-tagged Pf Hsp90 (P and FP, respec-
tively) with a plate growth assay. (B) Plate growth assay with all four Hsp90 tester
strains. F and FP were spotted 1 day earlier (hence the indication +1d for one addi-
tional day) and the image was acquired on day 4 (relative to when FY and F were
spotted). (C) Growth curves determined with liquid cultures. Cell density refers to











Fig. 4. Hsp90 tester strains show different sensitivities to Hsp90 inhibitors on plates. F and FP were spotted 1 day earlier (+1d) and the image was acquired on day 4. The
solvent DMSO (vehicle) was added as indicated in Section 2.
F) and Pf Hsp90 (FP) strains disappeared, GA was still more toxic
to FP. To reveal the differential sensitivities of the four strains to the
two drugs more clearly, cell densities in the presence of the drugs
were standardized to those of untreated cultures and expressed as
a ratio (Fig. 5D). FY, the strain that grows the most rapidly and is
only slightly affected by either drug, is relatively more inhibited by
GA for the ﬁrst 18h. In the presence of GA, it reaches saturation
about 6h later, but it does reach it, which is why the ratio drops
back down to 1 at 24h. Most importantly, this plot shows unam-
biguously that FP is hypersensitive to GA compared to Rd and that
in that respect it differs substantially from the strains with human
Hsp90 (F and F). Moreover, this quantitative result agrees with
the qualitative one from the plate assays, which already indicated
that FP is more sensitive to GA than Rd and hypersensitive to GA by
comparison with strains expressing human Hsp90.
4. Discussion
The number of known Hsp90 substrates is contin-
uing to grow very rapidly (for an updated list, see
http://www.picard.ch/downloads/Hsp90interactors.pdf) as could
be expected for a molecular chaperone that may be the most
abundant cytosolic protein even in unstressed cells [24]. It is still
difﬁcult to provide a comprehensive list of the substrates that
account for the essential functions of Hsp90 for viability of both
unicellular and metazoan organisms. We now add Pf Hsp90 to
the list of heterologous Hsp90’s that can apparently fulﬁll at least
the essential functions of Hsp90 in yeast for vegetative growth in
standard growth media. Whatever these functions are exactly, they
must includemany of the ones that have been highlighted by global
biochemical and genetic analyses of Hsp90 interactions in this
organism [25–28]. The results of these genetic complementation
experiments underscore the high evolutionary conservation of
Hsp90 [29–32]. For example, yeast Hsp82 compared to human
Hsp90 and Pf Hsp90 is 59% and 58% identical, respectively. The
sequence identity drops to only 36% with the Escherichia coli Hsp90
ortholog htpG, which may explain why htpG fails to complement
yeast ([16], G. Palmer and DP, unpublished results). Despite the
remarkable complementation by heterologous Hsp90’s for viabil-
ity, this complementation is far from complete. In the absence of
the Hsp90 co-chaperone Sti1, C. elegans Hsp90 and human Hsp90
cannot support viability of yeast mutants [17]. Moreover, human
Hsp90 fails to support Ste11-dependent pheromone signaling in
yeast [19], and yeast and human Hsp90’s differ in their ability to
support several other endogenous and exogenous substrates [33].
These shortcomings are mirrored by our ﬁndings that human and
Pf Hsp90’s do not support wild-type growth rates (Figs. 3–5). This
is particularly evident for the strain with Pf Hsp90, which grows
substantially more slowly than our control yeast strain with Hsp82.
It is noteworthy that the relative growth rates also differ
between liquid and solid media. It is a well-known phenomenon
in S. cerevisiae that the genetic background can differentially affect
the ability of a strain to grow in a plate assay or in liquid culture
(see for example refs. [34–36]). With respect to Hsp90, our ﬁnd-
ings may indicate that different environmental conditions impose
subtly different Hsp90 substrate requirements, which are differ-
entially fulﬁlled by different Hsp90 proteins. While our results
demonstrate that heterologous Hsp90’s do not behave differently
because of vastly different expression levels, there are several other
parameters that can be considered. They might differ in their abil-
ity to bind and to cooperate with the yeast Hsp90 co-chaperones
or to process yeast substrates (see also afore-mentioned exam-
ples). Alternatively, they might not function optimally because of
differences in posttranslationalmodiﬁcations or because of the par-
ticulars of the chemical milieu of a yeast cell.
We found that all strains of the Hsp90 tester set are sensitive
to Hsp90 inhibitors, albeit to very different extents. Strain FY with
the yeast Hsp82 was the least sensitive one and the only one that
could eventually reach similar cell densities with drugs as without
drugs both on plates and in liquid culture. Higher concentrations
yet are necessary to inhibit growth of FY more strongly (data not
shown), in agreement with previous reports about the toxicity of
Hsp90 inhibitors to wild-type strains, notably in a pdr5 back-
ground [22,37]. At concentrations thatwere onlyminimally toxic to
the strain FY, the other three strainswere severely growth impaired.
Surprisingly, Piper and co-workers [33] have reported that a strain
with human Hsp90 displayed relative resistance to Rd compared
to strains with human Hsp90 or yeast Hsc82 or Hsp82. This dis-











Fig. 5. Hsp90 tester strains show different sensitivities to Hsp90 inhibitors in liquid
culture. Panels A, B and C show growth curves of cultures that were left untreated
(only solvent), treated with 2M Rd and 40M GA, respectively. The scale of the
Y-axes is logarithmic. Error bars indicate the standard deviation. The data plotted
in panel A is the same as that of panel C in Fig. 3, but here the scale of the Y-axis
is different. (D) This graph shows the ratios of standardized cell densities observed
with the two inhibitors. Note that the last time point of panels A–C is not computed
here and that the scale of the Y-axis is linear.
experimental set-ups. Different expression levels of the drug target,
Hsp90, could easily explain differences in drug sensitivity. While
we do not know whether Hsp90 and Hsp90 levels were simi-
lar in the afore-mentioned study, we can assert for our strains that
they differed by at most 2-fold (Fig. 2) because the two isoforms
were marked by the same epitope tag and thus recognized by the
same antibody with identical efﬁciency. Most notably, the levels
of human Hsp90 and Pf Hsp90 were very close to those of the
isogenic strain with yeast Hsp82.
Hsp90 inhibitor sensitivity is determined by a variety of param-
eters including cell permeability, export pumps, metabolism, and
the binding afﬁnity for Hsp90. Undoubtedly, the latter is the most
relevant in the context of the differential sensitivities of different
strains that only differ by the Hsp90 proteins they express. They
may have intrinsically different binding afﬁnities for one drug or
another. Whether that is the case for yeast, human and Pf Hsp90
is not known since, to the best of our knowledge, they have not
yet been measured side by side. Furthermore, the binding afﬁni-
ties of Hsp90 for inhibitors can be inﬂuenced by its interactions
with co-chaperones [17,22,37–41], which in turn may be modu-
lated by posttranslational modiﬁcations of Hsp90 (see for example
refs. [42–44]). Since we had found that the Hsp90 co-chaperone
p23 directly protects Hsp90 from binding inhibitors [22], we did
introduce the Pf p23 ortholog into yeast. Instead of improving Pf
Hsp90 function and resistance, expression of Pf p23 in FP further
compromised growth (data not shown). To reconstitute Pf Hsp90
function fully in yeast, it may be necessary to introduce the entire
or at least more of the Pf co-chaperone complement.
Whatever the reasons are for the observed differential sensi-
tivities, we believe that our results constitute a proof of principle
that it should be possible to use this set of yeast strains to screen
for Hsp90 inhibitors with an even larger differential between the
Hsp90 of the host and the Hsp90 of the deadly parasite. More-
over, the Hsp90 set could easily be expanded to includeHsp90 from
other unicellular parasites such as Trypanosomes and Leishmania.
In closing, we would like to emphasize that this is a powerful live
cell, but nevertheless artiﬁcial, screening tool. The efﬁciency and
parasite-speciﬁcity of candidate drugs will need to be ascertained
and further characterized in appropriate in vitro and in vivo systems
with the parasite itself.
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